Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing novel treatments for serious musculoskeletal diseases.

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Maze Therapeutics is a biopharmaceutical company focused on developing precision medicines for renal and metabolic diseases using human genetics.

Metsera is a clinical-stage biopharmaceutical company developing next-generation treatments for obesity and metabolic diseases using their innovative platforms and Nutrient-Stimulated Hormone analog peptides.

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Aktis Oncology is a clinical-stage biotechnology company developing a proprietary radiopharmaceutical pipeline, including Nectin-4-targeted miniprotein radioconjugates, for cancer treatment.

Parse Biosciences is a company that develops and commercializes scalable single-cell sequencing technologies for use in over 1,000 labs globally, aiming to expand its product range and market presence with its recent $50 million funding.